CD19 Has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: Implications of molecular mimicry for B cell adhesion and enterohemorrhagic escherichia coli pathogenesis

Journal of Experimental Medicine

Volumn 180, Issue 1, 1994, Pages 191-201

  Maloney, Mark D ^a   Lingwood, Clifford A ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CELL SURFACE RECEPTOR; GLOBOTRIAOSYLCERAMIDE; LYMPHOCYTE SURFACE MARKER; VEROTOXIN;

ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BINDING SITE; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; DAUDI CELL; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; B-LYMPHOCYTES; BACTERIAL TOXINS; BINDING SITES; CELL ADHESION; COLITIS; ESCHERICHIA COLI; GASTROINTESTINAL HEMORRHAGE; HUMAN; MOLECULAR SEQUENCE DATA; SHIGA-LIKE TOXIN I; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; TRIHEXOSYLCERAMIDES;

EID: 0028358087     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.180.1.191     Document Type: Article

References (67)

1. Karmali, M.A. 1989. Infection by Verocytotoxin-producing Escherichia coli. Clin. Microbiol. Rev. 2:15.
2. O’Brien, A.D., and R.K. Holmes. 1987. Shiga and Shiga-like toxins. Microbiol. Rev. 51:206.
3. Donohue-Rolfe, A., M. Jacewicz, and G.T. Keusch. 1989. Isolation and characterization of functional Shiga toxin subunits and renatured holotoxin. Mol. Microbiol. 3:1231.
4. Ramotar, K., B. Boyd, G. Tyrrell, J. Gariepy, C.A. Lingwood, and J. Brunton. 1990. Characterization of Shiga-like toxin 1 and VT1-B subunit purified from overproducing clones of the SLT1 cistron. Biochem. J. 272:805.
5. Endo, Y., K. Tsurugi, T. Yutsudo, Y. Takeda, K. Ogasawara, and K. Igarashi. 1988. Site of the action of a vero toxin (VT2) from Escherichia coli 0157:H7 and a Shiga toxin on eukaryotic ribosomes. Eur. J. Biochem. 171:45.
6. Saxena, S.K., A.D. O’Brien, and E.J. Ackerman. 1989. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J. Biol. Chem. 264:596.
7. Jacewicz, M., H. Clausen, E. Nudelman, A. Donohue-Rolfe, and G.T. Keusch. 1986. Pathogenesis of Shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosyl-ceramide. J. Exp Med. 163:1391.
8. Lindberg, A.A., J.E. Brown, N. Strömberg, M. Westling-Ryd, J.E. Schultz, and K.-A. Karlsson. 1987. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J. Biol. Chem. 262:1779.
9. Lingwood, C.A., H. Law, S. Richardson, M. Petrie, J.L. Brunton, S. DeGrandis, and M. Karmali. 1987. Glycolipid binding of purified and recombinant Escherichia co/i-produced verotoxin in vitro. J. Biol. Chem. 262:8834.
10. Waddell, T., A. Cohen, and C.A. Lingwood. 1990. Induction of verotoxin sensitivity in receptor deficient cell lines using the receptor glycolipid globotriosyl ceramide. Proc. Natl. Acad. Sci. USA. 87:7898.
11. DeGrandis, S.A., J. Ginsberg, M. Toone, S. Climie, J. Friesen, and J. Brunton. 1987. Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operation of bacteriophage H-19B. J. Bacteriol. 169:4313.
12. Samuel, J.E., L.P. Perera, S. Ward, A.D. O’Brien, V. Ginsburg, and H.C. Krivan. 1990. Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants. Infect. Immun. 58:611.
13. MacLeod, D.L., C.L. Gyles, and B.P. Wilcock. 1991. Reproduction of edema disease of swine with purified Shiga-like toxin-II variant. Vet. Pathol. 28:66.
14. DeGrandis, S., H. Law, J. Brunton, C. Gyles, and C.A. Ling-wood. 1989. Globotetraosyl ceramide is recognized by the pig edema disease toxin. J. Biol. Chem. 264:12520.
15. Waddell, T., S. Head, M. Petrie, A. Cohen, and C.A. Ling-wood. 1988. Globotriosyl ceramide is specifically recognized by the E. coli verocytotoxin 2. Biochem. Biophys. Res. Commun. 152:674.
16. Lingwood, C.A. 1994. Verotoxin-binding in human renal sections. Nephron. 66:21.
17. Murray, L.J., J.A. Habeshaw, J. Wiels, and M.F. Greaves. 1985. Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells. Int. J. Cancer. 36:561.
18. Mangeney, M., Y. Richard, D. Coulaud, T. Tursz, andj. Wiels. 1991. CD77: an antigen of germinal center B cells entering apoptosis. Eur. J. Immunol. 21:1131.
19. Cohen, A., V. Madrid-Marina, Z. Estrov, M. Freedman, C.A. Lingwood, and H.-M. Dosch. 1990. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int. Immunol. 2:1.
20. Keusch, G., M. Jacewicz, M. Levine, R. Hornick, and S. Kochwa. 1976. Pathogenesis of Shigella diarrhea. Serum anticytotoxic antibody response produced by toxigenic and nontoxigenic Shigella dysenteriae. J. Clin. Invest. 57:194.
21. Nudelman, E., R. Kannagi, S. Hakomori, M. Parsons, M. Lipinski, J. Wiels, M. Fellows, and T. lursz. 1983. A glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody. Science (Wash. DC). 220:509.
22. Cohen, A., G.E. Hannigan, B.R.G. Williams, and C.A. Lingwood. 1987. Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor.J. Biol. Chem. 262:17088.
23. Lingwood, C.A., and S.C.K. Yiu. 1992. Glycolipid modification of α-interferon binding: Sequence similarity between α-interferon receptor and the verotoxin (Shiga-like toxin) B-subunit. Biochem. J. 283:25.
24. Uze, G., G. Lutfalla, and I. Gresser. 1990. Genetic transfer of a functional human interferon α-receptor into mouse cells: cloning and expression of its cDNA. Cell. 60:225.
25. Ghislain, J., C. Lingwood, M. Maloney, L. Penn, and E. Fish. 1992. Association between the alpha-interferon receptor and the membrane glycolipid globotriaosyl ceramide. Annual Meeting of the International Society of Interferon Research. 12:S114. (Abstr.).
26. Maloney, M., and C. Lingwood. 1993. Interaction of verotoxins with glycosphingolipids. TIGG (Trends in Glycoscience and Glycotechnology). 5:23.
27. Nadler, L., K. Anderson, G. Marti, M. Bartes, E. Park, J. Daley, and S. Schlossman. 1983. B4, a human B lymphocyte associated antigen expressed on normal, mitogen activated and malignant B lymphocytes. J. Immunol. 131:244.
28. Bradbury, L.E., V.S. Goldmacher, and T.F. Tedder. 1993. The CD19 signal transduction complex of B lymphocytes: the CD19 cytoplasmic domain alters signal transduction but not complex formation with TAPA-1 and Leu 13.J. Immunol. 151:2915.
29. Matsumoto, A.K., D.R. Martin, R.H. Carter, L.B. Klickstein, J.M. Ahearn, and D.T. Fearon. 1993. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J. Exp. Med. 178:1407.
30. Pesando, J.M., L.S. Bouchard, and B.E. McMaster. 1989. CD19 is functionally and physically associated with surface immunoglobulin. J. Exp Med. 170:2159.
31. Bradbury, L.E., G.S. Kansas, S. Levy, R.L. Evans, and T.F. Tedder. 1992. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 149:2841.
32. Callard, R.E., K.P. Rigley, S.H. Smith, S. Thurstan, and J.G. Shields. 1992. CD19 regulation of human B cell responses. B cell proliferation and antibody secretion are inhibited or enhanced by ligation of the CD19 surface glycoprotein depending on the stimulating signal used. J. Immunol. 148:2983.
33. de Rie, M.A., T.N. Schumacher, G.M. van Schijndel, and R.A. van Lier Miedema, F. 1989. Regulatory role of CD19 molecules in B-cell activation and differentiation. Cell. Immunol. 118:368.
34. Carter, R.H., D.A. Tuveson, D.J. Park, S.G. Rhee, and D.T. Fearon. 1991. The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J. Immunol. 147:3663.
35. Carter, R.H., and D.T. Fearon. 1992. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science (Wash. DC). 256:105.
36. Uckun, F.M., A.L. Burkhardt, L. Jarvis, X. Jun, B. Stealey, I. Dibirdik, D. Myers, L. Tuel-Ahlgren, and J.B. Bolen. 1993. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J. Biol. Chem. 268:21172.
37. Zhou, L., D. Ord, A. Hughes, and T. Tedder. 1991. Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig lymphocytes. Conservation of the extensive cytoplasmic domain. J. Immunol. 147:1424.
38. Boyd, B., G. Tyrrell, M. Maloney, C. Gyles, J. Brunton, and C. Lingwood. 1993. Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targeting and results in a VTl-like disease in pigs. J. Exp Med. 177:1745.
39. Armstrong, G.D., E. Fodor, and R. Vanmaele. 1991. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences. J. Infect. Dis. 164:1160.
40. Tedder, T.F., and C.M. Isaacs. 1989. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily, J. Immunol. 143:712.
41. Stamenkovic, I., and B. Seed. 1988. CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J. Exp Med. 168:1205.
42. Stein, P.E., A. Boodhoo, G.J. Tyrrell, J.L. Brunton, and RJ. Read. 1992. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature (Lond.). 355:748.
43. Wiels, J., M. Fellous, and T. Tursz. 1981. Monoclonal antibody against a Burkitt-lymphoma-associated antigen. Proc Natl. Acad. Sci. USA. 78:6485.
44. Tyrrell, G.J., K. Ramotar, B. Toye, B. Boyd, C.A. Lingwood, and J.L. Brunton. 1992. Alteration of the glycolipid specificity of VTE and VT1 by site-directed mutagenesis. Proc Natl. Acad. Sci. USA. 89:524.
45. Lingwood, C.A. 1993. Verotoxins and their glycolipid receptors. Adv. Lipid Res. 25:189.
46. Sandvig, K., K. Prydz, M. Ryd, and B. van Deurs. 1991. En-docytosis and intracellular transport of the glycolipid-binding ligand Shiga toxin in polarized MDCK cells. J. Cell Biol. 113:553.
47. van de Kar, N.C.A.J., L.A.H. Monnens, M. Karmali, and V.W.M. van Hinsbergh. 1992. Tumor necrosis factor and interleukin-1 induce expression of the verotoxin receptor globotri-aosyl ceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome. Blood. 80:2755.
48. Lingwood, C.A. 1991. Glycolipids as receptors. Adv. Lipid Res. 1:39.
49. Gregory, G.D., C.F. Edwards, A. Milner, J. Wiels, M. Lipinski, M. Rowe, T. Tursz, and A.B. Rickinson. 1988. Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus. Int.J. Cancer. 42:213.
50. Gregory, C.D., T. Tursz, C.F. Edwards, C. Tetaud, M. Talbot, B. Caillou, A.B. Rickinson, and M. Lipinski. 1987. Identification of a subset of normal B cells with a Burkitt’s lymphoma (BL)-like phenotype. J. Immunol. 139:313.
51. Mangeney, M., C.A. Lingwood, B. Caillou, S. Taga, T. Tursz, and J. Wiels. 1993. Apoptosis induced in Burkitt’s lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 53:5314.
52. Murzin, A.G. 1993. OB (oligonucleotide/oligosaccharidebind-ing)-fold: common structural and functional solution for nonhomologous sequences. EMBO (Eur. Mol. Biol. Organ.)J. 12:861.
53. Jackson, M.P., E.A. Wadolkowski, D.L. Weinstein, R.K. Holmes, and A.D. O’Brien. 1990. Functional analysis of the Shiga toxin and Shiga-like toxin type II variant binding subunits by using site-directed mutagenesis. J. Bacteriol. 172:653.
54. Perera, L.P., J.E. Samuel, R.K. Holmes, and A.D. O’Brien. 1991. Identification of three amino acid residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity. J. Bacteriol. 173:1151.
55. Tyrrell, D., P. James, N. Rao, C. Foxall, S. Abbas, F. Das-gupta, M. Nashed, A. Hasegawa, M. Kiso, and D. Asa et al. 1991. Structural requirements for the carbohydrate ligand of E-selectin. Proc Natl. Acad. Sci. USA. 88:10372.
56. Smith, S.H., K.P. Rigley, and R.E. Callard. 1991. Activation of human B cells through the CD19 surface antigen results in homotypic adhesion by LFA-l-dependent and -independent mechanisms. Immunology. 73:293.
57. Sandvig, K., O. Garred, K. Prydz, J. Kozlov, S. Hansen, and B. van Deurs. 1992. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature (Lond.). 358:510.
58. Schriever, F., A.S. Freedman, G. Freeman, E. Messner, G. Lee, J. Daley, and L.M. Nadler. 1989. Isolated human follicular dendritic cells display a unique antigenic phenotype. J. Exp Med. 169:2043.
59. Pallesen, G., and J. Zeuthen. 1987. Distribution of the Burkitt’s-lymphoma-associated antigen (BLA) in normal human tissue and malignant lymphoma as defined by immunohistological staining with monoclonal antibody 38.13. J. Cancer Res. Clin. Oncol. 113:78.
60. Kansas, G.S., and T.F. Tedder. 1991. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-l-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J. Immunol. 147:4094.
61. Evans, S.S., R.P. Collea, J.A. Leasure, and D.B. Lee. 1993. IFN-a induces homotypic adhesion and Leu-13 expression in human B lymphoid cells. J. Immunol. 150:736.
62. Wiels, J., M. Mangeney, C. Tetaud, and T. Tursz. 1991. Sequential shifts in the three major glycosphingolipid series are associated with B cell differentiation. Int. Immunol. 3:1289.
63. Louise, C.B., and T.G. Obrig. 1991. Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1β, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect. Immun. 59:4173.
64. Obrig, T., C. Louise, C. Lingwood, B. Boyd, L. Barley-Maloney, and T. Daniel. 1993. Endothelial heterogeneity in Shiga toxin receptors and responses. J. Biol. Chem. 268:15484.
65. Gillard, B.K., M.A. Jones, A.A. Turner, D.E. Lewis, and D.M. Marcus. 1990. Interferon-γ alters expression of endothelial cell-surface glycosphingolipids. Arch. Biochem. Biophys. 279:122.
66. Hughes, R.C. 1992. Lectins as cell adhesion molecules. Curr. Opin. Struct. Biol. 2:687.
67. Karmali, M.A., M. Petrie, M. Winkler, M. Bielaszewska, J. Brunton, N. van de Kar, T. Morooka, G.B. Nair, S.E. Richardson, and G.S. Arbus. 1994. Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli vero cytotoxin 1. J. Clin. Microbiol. In press.